Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor With a Heat Shock Protein-90 Inhibitory Profile, in Patients With Advanced Solid Tumors
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-08-0376
Full Text
Open PDFAbstract
Available in full text
Date
October 15, 2008
Authors
Publisher
American Association for Cancer Research (AACR)